According to the World Health Organisation (WHO), neglected tropical diseases (NTDs) are a diverse group of communicable diseases that prevail in tropical and sub-tropical conditions. They are thought to affect over one billion people worldwide and can cost developing economies billions of dollars every year.
Included in the list of NTDs are: dengue and chikungunya, leprosy, rabies, scabies, and snakebite envenoming.
WHO's NTD Roadmap has outlined targets to eliminate many and eradicate at least two NTDs by 2020. And now researchers from the Liverpool School of Tropical Medicine (LSTM) believe they have found a way to help tackle the global issue of NTDs.
The research team, with colleagues across the COUNTDOWN Consortium, investigated whether the global network of polio labs could help in addressing NTDs.
As LSTM explains, the WHO established the Global Polio Laboratory Network (GPLN) in 1988 as part of its plans to eradicate polio. The network is made up of 145 labs around the world, and local health clinics send samples from individuals presenting signs of polio to the labs, which then test the samples using the necessary culture screens and gene-based PCR tests to diagnose the disease.
The team examined the possibility of expanding the tests conducted at GPLN labs to include other pathogens considered to be of public health importance. They focused on soil-transmitted parasitic worms, helminths and Schistosoma. The findings of the study, which was carried out at the Ghana GPLN lab, were published in PLOS Neglected Tropical Diseases.
PhD student and first author, Lucas Cunningham, said: "The successful campaign waged against polio has eliminated the disease from most countries where it was once endemic, but there remains a group of diseases, namely NTDs, that affect about a billion people.
"We set out to see if these laboratories could be potentially expanded to address the need for a molecular diagnostic platform to NTDs, taking advantage of the Ghanaian lab's accumulated experience and resources."
The pilot study tested 448 faecal samples at the Ghana GPLN lab and successfully tested for helminths, identifying a prevalence of 22% for the combined helminth infections. The researchers noted that the design of the current study was not suitable to make any epidemiological conclusions, however, it was able to demonstrate the suitability of adapting a GPLN lab for the detection of helminths. Although there was no surveillance system, 1% of the samples were found to be infected with Strongyloides.
Dr Emily Adams, senior lecturer in Diagnostics for Infectious Disease and senior author of the paper, commented: "The study demonstrates a potential way forward in the monitoring and control of neglected tropical diseases that could be adapted and included in the legacy plan of the Global Polio Laboratory Network."
She added that the research team was looking forward to working together as they move forward.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial